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Forward-Looking Statements and Disclaimers
• This presentation contains forward-looking information and statements which constitute “forwardlooking information” under Canadian securities law and which may be material regarding, among
other things, the Company’s beliefs, plans, objectives, estimates, intentions and expectations.
Forward-looking information and statements are typically identified by words such as
“anticipate”, “believe”, “expect”, “estimate”, “forecast”, “goal”, “intend”, “plan”, “will”, “may
”, “should”, “could” and similar expressions. Specific forward-looking information in this document
includes, but is not limited to, statements with respect to the Company’s future operating and
financial results, its research and development activities, its capital expenditure plans and the
ability to execute on its future operating, investing and financing strategies. These forwardlooking information and statements, by their nature, necessarily involve risks and uncertainties
that could cause actual results to differ materially from those contemplated by these forwardlooking statements. We consider the assumptions on which these forward-looking statements are
based to be reasonable, but caution the reader that these assumptions regarding future
events, many of which are beyond our control, may ultimately prove to be incorrect since they are
subject to risks and uncertainties that affect us. Additional information regarding risk factors can
be found in the Medicago Annual Information Form filed on March 29, 2012.
• Our statements of “belief” in respect of our product and partner product candidates are based
primarily upon our results derived to date from our research and development program. We believe
that we have a reasonable scientific basis upon which we have made such statements. It is not
possible, however, to predict, based upon studies in vitro and animal studies whether a new
therapeutic agent or technology will be proved to be safe and/or effective in humans. We cannot
assure that the particular results expected by us will occur.

© 2012 Medicago Inc.
All rights reserved

• Any forward-looking statements and statements of “belief” represent our estimates only and
should not be relied upon as representing our estimates as of any subsequent date. Except as
required by law, we do not assume any obligation to update any forward looking statements or
statements of “belief”. We disclaim any intention or obligation to update or revise any forwardlooking statements or statements of “belief”, whether as a result of new information, future
events or otherwise. Nothing herein should be construed as an Offering of securities of the
Company in any jurisdictions.
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Reengineering vaccine design and production
(beyond pandemic)
• Strains with pandemic potential are circulating every year;
experts agree only a matter of time before a highly lethal
strain develops due to strain mutations
– Kawaoka’s & Fouchier’s studies

• Rapid response in pandemic vaccine production is needed to
address rapid rates of infection & minimize deaths
– In 2009 pandemic, time required to manufacture both egg- &
cell-based vaccines resulted in “too little, too late” vaccine
responses  no significant impact*

• Need for flexible technologies to respond to emerging or
engineered biothreats
– Multi-product platform
© 2012 Medicago Inc.
All rights reserved

*Ref: Osterholm & Kelley (2012) Mammalian-transmissible H5N1 influenza: Facts and Perspective.
mBio 3(2) doi:10.1128/mBio.00045-12
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Medicago overview
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Focus

Vaccines & Protein-based pharmaceuticals

Manufacturing technology

Transient expression in Tobacco

Vaccine technology

Virus-like particles

Vaccine discovery platform

VLPExpress

Headquarters, laboratories &
cGMP facilities

Quebec City, CANADA
Research Triangle Park, NC, USA
Genopole d’Evry, FRANCE

Agreements

Mitsubishi Tanabe Pharma – Strategic Alliance
DARPA Award – US$21M
IDRI – Phase I H5 GLA, intradermal
Pharma & U.S. Army – Vaccines outside of flu

$35M & 12 months to build
Capacity of 10M doses/month
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Products
Preclinical Phase 1
Pandemic influenza
H5
H5 – Intradermal+GLA
H1

Seasonal influenza
Quadrivalent

Rabies
Top 10 Pharma

Undisclosed
Ebola
Rotavirus

© 2012 Medicago Inc.
All rights reserved

Phase 2

Phase 3
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Protalix is paving the way…
First plant-derived pharmaceutical approved by FDA on
May 1st, 2012

© 2012 Medicago Inc.
All rights reserved
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Medicago’s manufacturing technology
Proprietary platform for the production recombinant proteins based on
a transient expression technology in plants (N. benthamiana)

Plants & Agrobacterium
preparation

Infiltration

Incubation

Medicago VLP

Extraction

Influenza virus

Purification

• 19 days to 1st lot
• Rapid lot-release:
• HA content
• 14-days sterility test
© 2012 Medicago Inc.
All rights reserved
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Characteristics of the plant-made H5 VLP vaccine
• Lot-release assays include purity, potency by SRID, lipid and protein
content, residual DNA, endotoxins, nicotine and anabasine content,
sterility
• Additional characterization such as SEC, NTA, MFI, PDI, glycans
• Product purity 98% (HA0, HA1, HA2)
Coomassie Western
stained SDS blot
PAGE

Silver stained
SDS PAGE

KDa
KDa
225
150
100
75
50
35
25
15
© 2012 Medicago Inc.
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HA dimers

225
150

HA0
HA1
HA2

100
75
50
35
25
15

HA dimers
HA0
HA1
HA2
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Redness
Swelling

Placebo Phase 2 part A

Non-adjuvanted H5 VLP

Adjuvanted H5 VLP

Placebo Phase 1

Non-adjuvanted H1 VLP

Placebo Phase 2 part A

Non-adjuvanted H5 VLP

Adjuvanted H5 VLP

Placebo Phase 1

Non-adjuvanted H1 VLP

Placebo Phase 2 part A

Non-adjuvanted H5 VLP

Adjuvanted H5 VLP

Placebo Phase 1

Non-adjuvanted H1 VLP

% of incidence
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General safety profile

Phase 1 H1 VLP and Phase 2 part A H5 VLP
70

60

50

40

30

20

10
Severe

0
Moderate

Pain

Solicited local AEs

Similar profiles were observed for systemic AEs
Mild
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Safety
IgE to plant glycans
Clinical trial Group

Number of
subjects with
IgEs ≥grade 1
to bromelain
at screening

Number of
subjects that
showed an IgE
increase after
vaccination

3.5%

0%

1.8%

(2/57)

(0/57)

(1/56)

0%

0%

0%

(0/20)

(0/20)

(0/20)

0%

0%

0%

(0/20)

(0/20)

(0/20)

3%

0%

3%

(6/191)

(0/188)

(6/191)

7%

0%

4%

(2/29)

(0/29)

(1/27)

0%

0%

0%

(0/28)

(0/28)

(0/28)

Phase 1 with Non-adjuvanted
H1 VLP (one VLP (n=58)
dose)
Fluzone
(trivalent, n=20)
Placebo (n=20)
Phase 2 with Adjuvanted VLP
H5 VLP (two (n=192)
doses)
Non-adjuvanted
VLP (n=29)
Placebo (n=27)

•
© 2012 Medicago Inc.
All rights reserved

Number of
subjects that
showed
detectable IgEs
6 months after
vaccination

No onset of allergic reactions correlating with in vitro assay
(manuscript in preparation)
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Antibody response – H5 VLP
HI test
Seroconversion rate after two doses of H5 VLP (18-64 years of age)

H5 VLP Vaccine

Phase I*
(groups of 12 subj.)

Phase II (part
A, groups of 30
subj)

*
© 2012 Medicago Inc.
All rights reserved

5 µg +Al

10 µg
+Al

20 µg
+Al

30 µg
+Al

45 µg
+Al

45 µg

16.7

25.0

58.3

(0.02-0.48)

(0.06-0.57)

(0.28-0.85)

58.6

53.6

46.7

21.4

(0.39-0.77)

(0.34-0.73)

(0.28-0.66)

(0.08-0.41)

12

Antibody response – H5 VLP
Phase II trial part B
Seroconversion rates after two doses

H5 VLP Vaccine, 20 µg dose + alum
18-29
n=23

30-39
n=22

40-49
n=26

50-60
n=26

HI test

56.5%

45.5%

38.5%

50.0%

SRH test

52.2%

40.9%

50.0%

42.3%

MN test

52.2%

50.0%

50.0%

50.0%

All vaccine doses statistically different from placebo

© 2012 Medicago Inc.
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H5 VLP vaccine equally immunogenic in young and older adults
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Duration of antibody response – H5 VLP
HI titers for homologous strain

Dose of
H5 VLP
(µg)

% of subjects with positive antibody response
(n = 15)
Prevaccination

After 1st
dose

After 2nd
dose

6-month
after boost

20 + alum

0

23,3

75,9

69,0

30 + alum

0

24,1

75,0

50,0

45 + alum

0

23,3

73,3

60,0

45

0

10,7

64,3

40,7

Placebo

0

0

0

8,0

Alum showed benefit on the antibody level for the H5 VLP vaccine
although formulation not optimized at high vaccine dosages
© 2012 Medicago Inc.
All rights reserved
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Antibody response – H1 VLP
HI test
Seroconversion rate after one single non-adjuvanted dose of H1 VLP
(18-49 years of age)

H1 VLP Vaccine (groups of 20 subj.)

© 2012 Medicago Inc.
All rights reserved

5 µg

13 µg

28 µg

61.1

63.2

82.4

(0.36-0.83)

(0.38-0.84)

(0.60-0.97)
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H1 VLP Vaccine Induced a Long Lasting
Memory Multifunctional T cell Response

H1 (VLP) Response
Per 106 CD45RA- CD4+ T cells
© 2012 Medicago Inc.
All rights reserved

Memory CD8+ T Cells

H1 (VLP) Response
Per 106 CD45RA- CD8+ T cells

Memory CD4+ T Cells

Polyfunctional T cells
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H1 VLP Vaccine Induces Cross-Reactive CD4+ T cell
Responses against HA (H5N1)

Responding Cells
per 106 CD4+ T cells

Total CD4+ T cell response against HA (H1N1) :
• PBMC at +6 month post-vaccine
• In vitro stimulation with H5 VLP and cytokine detection

Similar results
obtained for CD8+
T cell responses

Placebo
© 2012 Medicago Inc.
All rights reserved

H1 VLP
* P<0.05 (Mann-Whitney)
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Main conclusions from clinical trials
• Safety
–
–
–
–
–
–

Safe and well tolerated
More than 400 subjects dosed
1 or 2 doses
With or without alum
Dosages up to 45 µg
No onset of allergic reactions

• Immunogenicity
– The HA-VLP vaccine induces durable antibody response
– Durable, poly-functional and cross-reactive T Cell
responses to influenza HA antigens
– Strong innate immune response induced (data not shown)

© 2012 Medicago Inc.
All rights reserved
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Expanding the applications of the manufacturing
and vaccine platforms
• Can the manufacturing and vaccine platforms also
produce VLPs presenting non-influenza antigens?
– different genomic organization (RNA, DNA, polyprotein…)
– different envelope proteins structure
– different budding sites and requirements

Influenza

© 2012 Medicago Inc.
All rights reserved

RSV

Hepatitis C

HIV

Human papillomavirus
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VLPExpress: Accelerating the discovery of VLPbased vaccines
• Scale-down of manufacturing
technology
– HT cloning (96 DNA constructs in
10 days)
– Automated HT infiltration (50
expression strategies/days)
– HT monitoring of viral protein and
VLP accumulation
– Generic purification method

• Screening
– Capacity improved 10X
– Time to identification 10X faster

© 2012 Medicago Inc.
All rights reserved
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Flexibility:
Broadening applications of manufacturing & vaccine platforms
• Throughput of VLPExpress enables running multiple projects in parallel
• In 2011, the discovery team has tested >2,000 engineering approaches
and identified those driving the assembly of VLPs for 7 different families
of viruses:
–
–
–
–
–
–
–

Influenza (including 20 sub-types)
Rabies
Proprietary undisclosed enveloped VLP
Ebolavirus
Varicella-zoster virus
HIV
Partnered undisclosed capsid VLP

• Advantages
–
–
–
–
–

© 2012 Medicago Inc.
All rights reserved

Testing of multiple expression vectors in parallel
Comparing different protein engineering strategies
Co-expressing various proteins using separate Agrobacteria
Rapid optimization of expression conditions
Allow development of vaccines with "built-in" efficacy and manufacturing
readiness

21

Advantages of Medicago’s plant-based technology
• Pandemic
– Target any HA sequence including wild-type
– Induce strong antibody responses
– Induce a balanced immune response
• Strong CD4+ and CD8+ memory
• Cross-reactive for other strains

– More durable strain-specific immunity
– Superior cross-reactivity
– Possible role in the elderly

• Other emerging threats
– Many features of plant-made influenza VLPs vaccines
applicable to other indications (natural or man-made)
– Flexibility, speed, scale-up & cost advantages

© 2012 Medicago Inc.
All rights reserved
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